Get informed when a big investor buys or sells
+ FollowNovember 17, 2026 - AI Summary
Overvalued by 77.2% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $8.10 Billion |
|---|---|
| Enterprise Value | $6.57 Billion |
| Annual dividend | $0.24 |
| Dividend yield | 0.64% |
| Earnings per Share | $5.41 |
| Beta | 0.71 |
| Outstanding Shares | 221,879,092 |
| P/E Ratio | 40.72 |
|---|---|
| PEG | 266.39 |
| Price to Sales | 1.18 |
| Price to Book Ratio | 1.14 |
| Enterprise Value to Revenue | 0.93 |
| Enterprise Value to EBIT | 3.45 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.07 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe,...